FDA Grants Fast Track to Onvansertib in Colorectal Cancer
Cardiff Oncology's onvansertib combination is designated for first-line KRAS- or NRAS-mutated metastatic colorectal cancer.
Updated on Nov. 16, 2026 in Cancer

The FDA granted fast track designation to onvansertib plus FOLFIRI and bevacizumab for first-line treatment of KRAS- or NRAS-mutated metastatic colorectal cancer. The designation follows results from the randomized phase 2 CRDF-004 trial.
Why it matters
No first-line therapies are specifically approved for patients with RAS-mutated metastatic colorectal cancer, leaving a gap in treatment options for this group. Fast track designation is intended to speed development and review of therapies addressing serious conditions with unmet need.
In the randomized phase 2 CRDF-004 trial of 110 patients, the onvansertib combination produced a confirmed objective response rate of 72.2% in the intent-to-treat population, compared with 42.1% for FOLFIRI plus bevacizumab alone. Median progression-free survival had not been reached for the combination arm as of the September 28, 2026 data cutoff, while pooled standard-of-care arms reached approximately 11 months.
The players
Cardiff Oncology
Cardiff Oncology is a publicly traded clinical-stage oncology company developing targeted cancer therapies, including onvansertib, a PLK1 inhibitor.
The details
The CRDF-004 trial randomly assigned patients to oral onvansertib at 20 mg or 30 mg on days 1 through 5 and 15 through 19 of 28-day cycles, alongside FOLFIRI and bevacizumab or FOLFOX and bevacizumab. Every patient still receiving the onvansertib-based combination had been treated for 21 months or longer.
Timeline
February 2024: Enrollment in the CRDF-004 trial began at U.S. sites.
September 28, 2026: Data cutoff for median progression-free survival in the combination arm.
November 16, 2026: FDA fast track designation for metastatic colorectal cancer was announced.
Health Landscape
The fast track designation places onvansertib within the FDA's expedited development pathway, which is designed to accelerate therapies for serious conditions with unmet medical need. It positions the combination as a potential first-line option in RAS-mutated metastatic colorectal cancer, a population for which approved targeted first-line options remain absent.
For patients with RAS-mutated metastatic colorectal cancer, fast track designation signals a potential new first-line option that is still under study and not yet approved. Patients and clinicians can track the ongoing development through the trial record before any therapy becomes available.
The takeaway
Fast track designation does not equal approval, so the onvansertib combination remains investigational. Readers following colorectal cancer care should watch for phase 3 results before expecting changes to standard first-line treatment.
Further reading
Explore more on Cancer treatment research and clinical trial developments.
More information
Review the ClinicalTrials.gov record for the CRDF-004 onvansertib trial for full study details.






